[{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TT-10","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"PORT-6","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tarus Therapeutics \/ Portage Biotech Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Portage Biotech Inc."},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TT-10","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tarus Therapeutics \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Tarus Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Tarus Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 14, 2022

                          Lead Product(s) : TT-10

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Portage Biotech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : $21.0 million

                          July 06, 2022

                          Lead Product(s) : PORT-6

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Portage Biotech

                          Deal Size : $53.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : TT-4, an oral small molecule drug targeting the Adenosine A2B receptor (A2BR). Tarus plans to initiate a Phase 1a/1b study in the third quarter of 2021 to evaluate TT-4 in patients with advanced solid tumors both as a monotherapy and in combination.

                          Brand Name : TT-4

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 27, 2021

                          Lead Product(s) : TT-4

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The application includes extensive preclinical data on TT-4's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.

                          Brand Name : TT-4

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 28, 2021

                          Lead Product(s) : TT-4

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The application includes extensive preclinical data on TT-10's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.

                          Brand Name : TT-10

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 10, 2021

                          Lead Product(s) : TT-10

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank